PAST
Liver metastases may occur in up to 40% of patients with pancreatic neuroendocrine tumors (pNETs). 1 The management of this condition has largely been predicated on surgical resection whenever possible, which is associated with both long-term survival and symptomatic relief. 2, 3 Unlike liver metastases from other malignancies such as colorectal cancer for which the role of preoperative systemic therapy is well established even in the case of resectable disease, no such data exist for pancreatic neuroendocrine liver metastases (PNLM). Our group has previously demonstrated the efficacy of a regimen of 5-fluorouracil, doxorubicin, and streptozocin (FAS) in the metastatic and locally advanced pNET settings. In the current study, we sought to evaluate the outcomes associated with preoperative FAS in patients with PNLM who underwent hepatectomy.
PRESENT
The results of our study support a role for neoadjuvant FAS, which was associated with a high response rate on imaging criteria, in patients with PNLM, even those with resectable disease. 4 Despite more aggressive disease characteristics, patients who were treated with neoadjuvant FAS followed by hepatectomy experienced similar overall survival (OS) and recurrence-free survival (RFS) when compared with patients who underwent surgery first, with no significant difference in major postoperative complications. When only patients with synchronous PNLM were considered, preoperative FAS was associated with a OS and RFS benefit. Conversely, the treatment of patients with potentially resectable PNLM with FAS only was associated with significantly worse survival compared with treatment that included surgery. Taken together, our findings suggest that neoadjuvant FAS can be safely administered before surgery, and may have a role to play beyond conversion of unresectable disease, including the potential for improved survival among patients with synchronous disease.
FUTURE
Our findings, although limited in their significance by the retrospective nature of our single-institutional experience, lay the foundation for a prospective trial in which the role of preoperative FAS can be clearly defined for resectable PNLM. They also highlight the need for a multidisciplinary approach to this challenging clinical scenario for which multimodal treatment sequencing decisions must be weighed carefully. Surgery remains an essential component in the therapeutic approach to patients with resectable PNLM, but other treatment modalities may also be of importance. In addition, whether and when targeted therapies such as everolimus or sunitinib should be used in the context of resectable PNLM remains ill-defined and may be worth investigating.
